Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix

Journal of Clinical Investigation

Volumn 100, Issue 4, 1997, Pages 867-874

  Pillarisetti, Sivaram ^a   Paka, Latha ^a   Obunike, Joseph C ^a   Berglund, Lars ^a   Goldberg, Ira J ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Arteriosclerosis; Endothelial cells; Heparin; Oxidized LDL; Proteoglycans

Indexed keywords

FIBRONECTIN; HEPARIN LYASE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MATRIGEL; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEOHEPARAN SULFATE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0030769127     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119602     Document Type: Article

References (59)

1. Scanu, A.M., R.M. Lawn, and K. Berg. 1991. Lipoprotein (a) and atherosclerosis. Ann. Intern. Med. 115:209-218.
2. Hajjar, K.A., and R.L. Nachman. 1996. The role of lipoprotein (a) in atherogenesis and thrombogenesis. Annu. Rev. Med. 47:423-442.
3. Rhoads, G.G., G. Dahlen, K. Berg, N.E. Morton, and A.L. Dannenberg. 1986. Lipoprotein (a) as risk factor for myocardial infarction. J. Am. Med. Assoc. 256:2540-2544.
4. Dahlen, G.H. 1994. Lipoprotein (a) in cardiovascular disease. Atherosclerosis. 108:111-126.
5. Moliterno, D.J., R.A. Lange, R.S. Meidel, J.E. Willard, C.C. Leffert, R.D. Gerard, E. Boerwinkle, H.H. Hobbs, and L.D. Hillis. 1993. Relation of plasma Lp(a) to infarct artery patency in survivors of myocardial infarction. Circulation. 88:935-940.
6. Farrar, M., F.L. Gohme, and C.J. Albert. 1994. Coronary artery disease is associated with increased Lp(a) concentrations independent of the size of the circulating apo(a) isoforms. Arterioscler. Thromb. 14:1272-1283.
7. Rath, M., A. Neindorf, T. Reblin, M. Dietel, H.J. Krebber, and U. Beisiegel. 1989. Detection and quantification of Lp(a) in arterial wall of 107 coronary bypass patients. Atherosclerosis. 9:579-592.
8. Pepin, J.M., J.A. O'Neil, and H.F. Hoff. 1991. Quantification of apoB and apo(a) in human atherosclerotic lesions. J. Lipid Res. 32:317-327.
9. Kreuzer, J., M.B. Lloyd, D. Bok, G.M. Fless, A.M. Scanu, A.J. Lusis, and M.E. Haberland. 1994. Lp(a) displays increased accumulation compared to LDL in the murine arterial wall. Chem. Phys. Lipids. 67/68:175-190.
10. Nielsen, L.B., S. Stender, K. Kjeldsen, and B.G. Nordestgaard. 1996. Specific accumulation of Lp(a) in balloon-injured rabbit aorta in vivo. Circ. Res. 78:615-626.
11. Liu, A.C., and R.M. Lawn. 1994. Vascular interactions of Lp(a). Curr. Opin. Lipidol. 5:269-273.
12. Rouy, D., M.L. Koschinsky, V. Fleury, M.J. Chapman, and E. Angles-Cano. 1992. The binding of human recombinant apo(a) and plasminogen to fibrin surfaces. Biochemistry. 31:6333-6339.
13. Van der Hoek, Y., W. Sangarar, G.P. Cote, J.P. Kastelein, and M. Koschinsky. 1994. Binding of recombinant apo(a) to extracellular matrix proteins. Arterioscler. Thromb. 14:1792-1798.
14. Bihari-Varga, M., E. Gruber, M. Rotheneder, R. Zechner, and G.M. Kostner. 1988. Interaction of Lp(a) and LDL with glycosaminoglycans from human aorta. Arteriosclerosis.E 8:851-857.
15. Wight, T.N. 1995. The extracellular matrix and atherosclerosis. Curr. Opin. Lipidol. 6:326-334.
16. Timpl, R. 1994. Proteoglycans of basement membrane. EXS. 70:123-144.
17. Wight, T.N. 1989. Cell biology of arterial proteoglycans. Arteriosclerosis. 9:1020-1026.
18. Iozzo, R., I. Cohen, S. Grassel, and A. Murdoch. 1994. The biology of perlecan: the multifaceted HSPG of basement membranes and pericellular matrices. Biochem. J. 302:625-639.
19. Hoff, H.F., and W.D. Wagner. 1986. Plasma, low density lipoprotein accumulation in aortas of hypercholesterolemic swine correlates with modifications in aortic glycosaminoglycan composition. Atherosclerosis. 61:231-236.
20. Salisbury, E.G., D.P. Hajjar, and C.R. Minick. 1985. Altered glycosaminoglycan metabolism in injured arterial wall. Exp. Mol. Pathol. 42:306-319.
21. Wagner, W.D. 1985. Proteoglycan structure and function as related to atherosclerosis. Ann. NY Acad. Sci. 454:52-68.
22. Hollmann, J., A. Schmidt, D. von Bassewitz, and E. Buddecke. 1989. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta. Arteriosclerosis. 9:154-158.
23. Volker, W., A. Schmidt, W. Oortmann, T. Broszey, V. Faber, and E. Buddecke. 1990. Mapping of proteoglycans in atherosclerotic lesions. Eur. Heart J. 11:29-40.
24. Heinecke, J.W., H. Rosen, and A. Chait. 1984. Iron and copper promote modification of LDL by arterial smooth muscle cells. J. Clin. Invest. 74:1890-1894.
25. Kosugi, H., T. Kojima, and K. Kikugawa. 1989. Thiobarbituric acid reactive substances from peroxidized lipids. Lipids. 24:873-881.
26. Shepherd, J., K. Bedford, and H.G. Morgan. 1976. Radioiodination of human low density lipoprotein: a comparison of four methods. Clin. Chim. Acta. 66:97-101.
27. Sivaram, P., M.G. Klein, and I.J. Goldberg. 1992. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J. Biol. Chem. 267:16517-16522.
28. Stins, M.F., F.R. Maxfield, and I.J. Goldberg. 1992. Polarized binding of lipoprotein lipase to endothelial cells. Arterioscler. Thromb. 12:1437-1446.
29. Sivaram, P., J.C. Obunike, and I.J. Goldberg. 1995. Lysolecithin-induced alterations of subendothelial heparan sulfate proteoglycans increase monocyte binding to matrix. J. Biol. Chem. 270:29760-29765.
30. Kruth, H.S. 1985. Subendothelial accumulation of unesterified cholesterol: an early event in the development of atherosclerosis. Atherosclerosis. 57: 337-341.
31. Simionescu, N., E. Vasile, F. Lupu, G. Popescu, and M. Simionescu. 1986. Prelesional events in atherogenesis: accumulation of extracellular cholesterol rich liposomes in the arterial intima of hyperlipidemic rabbit. Am. J. Pathol. 123:1109-1125.
32. Guyton, J.R., and K.F. Klemp. 1996. Development of lipid rich core in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 16:4-11.
33. Schwenke, D., and T.E. Carew. 1989. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs selective increase in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 9: 908-913.
34. Frank, J.S., and A.M. Fogelman. 1989. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra rapid freezing and freeze etching. J. Lipid Res. 30:967-978.
35. Nievelstein-Post, P., G. Mottino, A. Fogelman, and J.S. Frank. 1994. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler. Thromb. 14:1151-1161.
36. Jamieson, C.G., D.C. Usher, D.J. Rader, and E. Lavi. 1995. Apo(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role of endothelial cells in lesion formation. Am. J. Pathol. 147:1567-1574.
37. Ernst, S., R. Langer, C. Cooney, and R. Sasisekharan. 1995. Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30:387-444.
38. Gallis, Z., G. Sukhova, M. Lark, and P. Libby. 1994. Increased expression of matrix metalloproteases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-2503.
39. Gallis, Z., G. Sukhova, R. Kranzhofer, S. Clark, and P. Libby. 1995. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. USA. 92:402-406.
40. Guretzki, H.J., K.D. Gerbitz, B. Olgemoller, and E. Schleicher. 1994. Atherogenic levels of LDL alter the permeability and composition of endothelial barrier. Atherosclerosis. 107:15-24.
41. Colburn, P., C.P. Dietrich, and V. Buonassisi. 1996. Alterations of heparan sulfate moieties in cultured endothelial cells exposed to endotoxin. Arch. Biochem. Biophys. 325:129-138.
42. Fisher, E.J., S.V. McLennan, D.R. Yue, and J.R. Turtle. 1994. Cell associated proteoglycans of retinal pericytes and endothelial cells. Modulation by glucose and ascorbic acid. Microvasc. Res. 48:179-189.
43. Grimm, J., R. Keller, and P.G. Groot. 1988. Laminar flow induces cell polarity and leads to rearrangement of proteoglycan metabolism in endothelial cells. Thromb. Haemostasis. 60:437-441.
44. Guretzki, H.J., E. Schleicher, K.D. Gerbitz, and B. Olgemoller. 1994. Heparin induces endothelial extracellular matrix alterations and barrier dysfunction. Am. J. Physiol. 267:C946-C954.
45. Hennig, B., D.W. Lipke, G.A. Boissonneault, and S. Ramasamy. 1995. Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Prostaglandins Leuko. Essent. Fatty Acids. 53:315-324.
46. Geller, R.L., N.S. Ihrcke, J. Maines, B.J. Lindman, and J.L. Platt. 1993. Loss of heparan sulfate as a manifestation of cellar immunity in vivo and in vitro. Transplant Proc. 25:144-145.
47. Oishi, K., R.L. Raynor, P.A. Charp, and J.F. Kuo. 1988. Regulation of protein kinase by lysophospholipids: potential role in signal transduction. J. Biol. Chem. 263:6865-6871.
48. Ohara, Y., T. Peterson, B. Zheng, J.F. Kuo, and D.G. Harrison. 1994. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler. Thromb. 14:1007-1013.
49. Watson, A.D., M. Navab, S. Hama, A. Sevanian, S.M. Prescott, D.M. Stafforini, T.M. McIntyre, A.M. Fogelman, and J.A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on production and action of minimally oxidized LDL. J. Clin. Invest. 95:774-782.
50. Watson, A.D., J.A. Berliner, S. Hama, B.N. LaDu, K.F. Faull, A.M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized LDL. J. Clin. Invest. 96:2882-2891.
51. Katsuda, S., Y. Okada, T. Minamoto, Y. Oda, Y. Matsui, and I. Nakanishi. 1992. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler. Thromb. 32:494-502.
52. Kakolyris, S., P. Karakitosis, M. Tzardi, and E. Agapitos. 1995. Immunohistochemical detection of fibronectin in early and advanced atherosclerosis. In Vivo (Attiki). 9:35-40.
53. Stenman, S., K. von Smitten, and A. Vaheri. 1980. Fibronectin and atherosclerosis. Acta Med. Scand. 642(Suppl.):165-170.
54. Tanouchi, J., M. Uematsu, A. Kitabatake, T. Masuyama, H. Ito, Y. Doi, M. Inoue, and T. Kamada. 1992. Sequential appearance of fibronectin, collagen and elastin during fatty streak initiation and maturation in hypercholesterolemic fat-fed rabbits. Jpn. Circ. J. 56:649-656.
55. Hynes, R.O., and K.M. Yamada. 1982. Fibronectins: multifunctional modular glycoproteins. J. Cell Biol. 95:369-377.
56. Salonen, E.M., M. Jauhianen, L. Zardi, A. Vaheri, and C. Ehnholm. 1989. Lp(a) binds to fibronectin and has serine protease activity capable of cleaving it. EMBO (Eur. Mol. Biol. Org.) J. 8:4035-4040.
57. Moser, T.M., J. Enghild, S. Pizzo, and M.S. Stack. 1993. The extracellular proteins laminin and fibronectin contain binding domains for plasminogen and tissue plasminogen activator. J. Biol. Chem. 268:18917-18923.
58. Skubitz, A.P., J.B. McCarthy, A.S. Charonis, and L.C. Furcht. 1988. Localization of three distinct heparin binding domains of laminin by monoclonal antibodies. J. Biol. Chem. 263:4861-4868.
59. Vlodavsky, I., H. Miao, B. Medalion, P. Danagher, and D. Ron. 1996. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis. Rev. 15:177-186.